Covid crisis spurs growing interest in drugmakers, diagnostics and medical equipment firms
UK drugmakers, diagnostics, medical equipment and other life sciences companies have raised £10.6bn from private funding rounds and stock market flotations in the first three months of the year, more than half of last year’s record total, according to a report.
Last year, investment into life sciences companies, including mergers and acquisitions, public listings, venture capital, and private equity, amounted to a nearly £20bn.
